Latest news


Extension of preclinical research collaboration agreement with a top-10 large pharma company

Posted on Jan 18, 2018

Oslo (Norway), 18 January 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2018, and may be further extended. The […]

PCI Biotech to present at Biotech Showcase 2018

Posted on Jan 8, 2018

Oslo, Norway, January 8, 2018 – PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at Biotech Showcase 2018 being held January 8-10, 2018 at the Hilton San Francisco Union Square, California, US. On Tuesday, January 9, 2018 at 04:00pm (PST), Dr. Per Walday, […]

PCI Biotech announces preliminary outcome of meetings with EMA and FDA for development of fimaporfin in inoperable cholangiocarcinoma

Posted on Dec 20, 2017

Oslo, 20 December 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced preliminary outcome of regulatory interactions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) on the development of fimaporfin in combination with gemcitabine for treatment of inoperable cholangiocarcinoma (bile duct cancer). The purpose of […]